Impalpable invisible stage T1c prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view

Journal of Urology

Volumn 157, Issue 1, 1997, Pages 244-250

  Elgamal, Abdel Aziz A ^a   Van Poppel, Hendrik P ^a   Van De Voorde, Wim M ^a   Van Dorpe, Jo A ^a   Oyen, Raymond H ^a   Baert, Luc V ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

biopsy; neoplasm staging; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURGICAL ANATOMY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0031060402     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65337-0     Document Type: Article

References (30)

1. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
2. Elgamal, A. A., Petrovich, Z., Van Poppel, H. and Baert, L.: The role of prostate specific antigen in the management of prostate cancer. In: Carcinoma of the Prostate: Innovations in Management. Edited by Z. Petrovich, L. Baert and L. W. Brady. New York: Springer-Verlag, chapt. 14, pp. 179-196, 1996.
3. Schröder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso, M.: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992.
4. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
5. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer., 20: 687, 1993.
6. Ohori, M., Wheeler, T. M. and Scardino, P. T.: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer, 74: 104, 1994.
7. Scaletscky, R., Koch, M. O., Eckstein, C. W., Bicknell, S. L., Gray, G. F., Jr. and Smith, J. A., Jr.: Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J. Urol., 152: 129, 1994.
8. Humphrey, P. A., Keetch, D. W., Smith, D. S., Shepherd, D. L. and Catalona, W. J.: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J. Urol., 155: 816, 1996.
9. Elgamal, A. A., Van de Voorde, W. M., Van Poppel, H. P., Lauweryns, J. M. and Baert, L. V.: Selective zonal distribution of tumor volume versus grade in T1c prostate cancer. J. Urol., part 2, 153: 484A, abstract 1024, 1995.
10. Schröder, F. H., van der Sluijs, J. W. and Rietbergen, J. B.: T1c prostatic cancer: definitions, clinical relevance and management. Eur. Urol. Update Series, 4: 66, 1995.
11. Smith, J. A., Jr.: Stage T1c prostate cancer: perspectives on clinical management. Sem. Urol. Oncol., 13: 238, 1995.
12. Dietrick, D. D., McNeal, J. E. and Stamey, T. A.: Core cancer length in ultrasound guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology, 45: 987, 1995.
13. Van de Voorde, W. M., Elgamal, A. A., Van Poppel, H. P., Verbeken, E. K., Baert, L. V., Lauweryns, J. M.: Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer, 74: 3164, 1994.
14. McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Amer. J. Surg. Path., 12: 897, 1988.
15. Gleason, D. F.: Histologic grading of prostate cancer: a perspective. Hum. Path., 23: 273, 1992.
16. Greene, D. R., Wheeler, T. M., Egawa, S., Dunn, J. K. and Scardino, P. T.: A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol., 146: 1069, 1991.
17. Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S. and Schmid, H. P.: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, suppl., 71: 933, 1993.
18. Stamey, T. A., Dietrick, D. D. and Issa, M. M.: Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J. Urol., 149: 510, 1993.
19. Tibblin, G., Welin, L., Bergström, R., Ronquist, G., Norlén, B.-J. and Adami, H.-O.: The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913. J. Urol., 154: 1386, 1995.
20. Aus, G., Hugosson, J. and Norlén, L.: Long-term survival and mortality in prostate cancer treated with noncurative intent. J. Urol., 154: 460, 1995.
21. 1-antichymotrypsin before diagnosis of prostate cancer. Lancet, 344: 1594, 1994.
22. Lerner, S. E., Seay, T. M., Blute, M. L., Bergstralh, E. J., Barrett, D. and Zincke, H.: Prostate specific antigen detected prostatic cancer (clinical stage T1c): an interim analysis. J. Urol., 155: 821, 1996.
23. Babaian, R. J., Troncoso, P., Steelhammer, L. C., Lloreta-Trull, J. and Ramirez, E. I.: Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J. Urol., 154: 1808, 1995.
24. Lui, P. D., Terris, M. K., McNeal, J. E. and Stamey, T. A.: Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. J. Urol., part 2, 153: 1000, 1995.
25. Van de Voorde, W. M., Van Poppel, H. P., Verbeken, E. K., Oyen, R. H., Baert, L. V. and Lauweryns, J. M.: Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. Mod. Path., 8: 591, 1995.
26. McNeal, J. E.: Prostatic microcarcinomas in relation to cancer origin and the evolution to clinical cancer. Cancer, suppl. 3, 71: 984, 1993.
27. Lee, F., Siders, D. B., Torp-Pedersen, S. T., Kirscht, J. L., McHugh, T. A. and Mitchell, A. E.: Prostate cancer: transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer. Cancer, suppl., 67: 1132, 1991.
28. deKernion, J. B.: Early detection and treatment of prostate cancer: radical prostatectomy for localized prostate cancer. Read at annual meeting of American Urological Association, Las Vegas, Nevada, April 23-28, 1995.
29. Goldstein, N. S., Bégin, L. R., Grody, W. W., Novak, J. M., Qian, J. and Bostwick, D. G.: Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the "vanishing cancer phenomenon." Amer. J. Surg. Path., 19: 1002, 1995.
30. Elgamal, A.-A. A., Cornillie, F. J., Van Poppel, H. P., Van de Voorde, W. M., McCabe, R. and Baert, L. V.: Free-to-total prostate specific antigen ratio as a single test for detection of significant Tic prostate cancer. J. Urol., 156: 1042, 1996.